

112/SE/BOM/2017/GBSL

7<sup>th</sup> December, 2017

To  
The Manager (CRD)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001

To  
The Manager  
National Stock Exchange Of India Limited  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code : 509079**

**Symbol : GUFICBIO**

Dear Sirs,

**Sub.: Revised Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2017.**

With reference to the outcome of the Board of Directors Meeting held on December 14, 2017 filed with the Stock Exchanges, we would like to inform that there were inadvertent errors in the Statement of Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2017.

Attached is the Revised Unaudited Financial Results along with the Statement of Assets & Liabilities and Unaudited Segment wise Results for the Quarter and Half Year Ended September 30, 2017.

You are requested to take the same on record.

Thanking You,

Yours Faithfully,

For Gufic Biosciences Limited



**Hemal M. Desai**  
CFO & Director  
DIN 07014744



# GUFIC BIOSCIENCES LIMITED

CIN : L65990MH1984PLC033519

Regd. Office: 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai 400 069.

Tel No: 022- 6726 1000 Fax. No: 022- 6726 1068

Email id: info@guficbio.com, website: www.gufic.com

## Statement of Unaudited Standalone Financial Results for the Quarter and Six Months ended 30th September, 2017

(Rs in Lakh) Except EPS

Sr. No.	Particulars	Quarter Ended			Six Months Ended	
		30th Sept, 2017 (Unaudited)	30th June, 2017 (Unaudited)	30th Sept, 2016 (Unaudited)	30th Sept, 2017 (Unaudited)	30th Sept, 2016 (Unaudited)
<b>I</b>	<b>Income</b>					
	(a) Revenue From Operations	7,484.95	6342.40	6648.22	13,827.35	12,526.60
	(b) Other Income	84.83	7.80	33.36	92.63	46.92
	<b>Total Income</b>	<b>7,569.78</b>	<b>6350.20</b>	<b>6681.58</b>	<b>13,919.98</b>	<b>12,573.52</b>
<b>II</b>	<b>Expenses</b>					
	(a) Cost Of material Consumed	3,509.60	1,198.26	2465.16	4,707.86	4,007.74
	(b) Excise Duty	0.00	315.52	229.01	315.52	597.52
	(b) Purchase of Stock-in-Trade	1,091.83	2,695.21	1057.16	3,787.04	2,184.67
	(c) Changes in inventories wip ,finished goods	(961.96)	(1,029.76)	(234.48)	(1,991.72)	-337.36
	(d) Employee Benefit expenses	1,232.42	1,091.61	1001.52	2,324.03	2,003.56
	(e) Finance Cost	269.21	175.53	141.66	444.74	279.47
	(f) Depreciation & Amortization	97.67	93.29	93.68	190.96	184.80
	ii. Other Expenses	1,636.98	1,330.04	1503.07	2,967.02	2,811.02
	iii. Foreign Exchange Adjustment	-	-	-	-	-
	<b>Total expenses</b>	<b>6,875.76</b>	<b>5,869.70</b>	<b>6,256.78</b>	<b>12,745.46</b>	<b>11,731.42</b>
<b>III</b>	<b>Profit /(Loss) before exceptional items and tax</b>	<b>694.02</b>	<b>480.50</b>	<b>424.80</b>	<b>1,174.52</b>	<b>842.10</b>
	Exceptional items	51.38	107.49	-	158.87	-
<b>IV</b>	<b>Profit/ (Loss) before tax</b>	<b>745.40</b>	<b>587.99</b>	<b>424.80</b>	<b>1,333.39</b>	<b>842.10</b>
<b>V</b>	<b>Tax Expense</b>					
	(a) Current tax	263.60	240.40	157.50	504.00	343.00
	(b) Deferred tax	(84.89)	(6.53)	1.92	(91.42)	(22.64)
<b>VI</b>	<b>Total tax expenses</b>	<b>178.71</b>	<b>233.87</b>	<b>159.42</b>	<b>412.58</b>	<b>320.36</b>
<b>VII</b>	<b>Profit /(Loss) for the period from continuing operations</b>	<b>566.69</b>	<b>354.12</b>	<b>265.38</b>	<b>920.81</b>	<b>521.74</b>
<b>VIII</b>	<b>Profit/(loss) from discontinued operations</b>	-	-	-	-	-
<b>IX</b>	<b>Tax expenses of discontinued operations</b>	-	-	-	-	-
<b>X</b>	<b>Profit/(loss) from Discontinued operations (after tax)</b>	-	-	-	-	-
<b>XI</b>	<b>Profit/(loss) for the period</b>	<b>566.69</b>	<b>354.12</b>	<b>265.38</b>	<b>920.81</b>	<b>521.74</b>
<b>XII</b>	<b>Other Comprehensive Income</b>	-	-	-0.17	-	-0.34
<b>XIII</b>	<b>Total Comprehensive Income</b>	<b>566.69</b>	<b>354.12</b>	<b>265.21</b>	<b>920.81</b>	<b>521.41</b>
<b>XIV</b>	<b>Details of equity share capital</b>					
	Paid-up Equity Share Capital (Face Value Re. 1/- each)	773.50	773.50	773.50	773.50	773.50
<b>XV</b>	<b>EPS (of Re. 1/- each) (Not Annualised)</b>					
	(a) Basic	0.73	0.46	0.34	1.19	0.67
	(b) Diluted	0.73	0.46	0.34	1.19	0.67





1 Statement of Assets and Liabilities :		AS AT
PARTICULARS		30th Sept, 2017 (Unaudited)
<b>A</b>	<b>ASSETS</b>	
<b>I</b>	<b>Non- Current Assets</b>	
	Property, Plant and equipment	2,284.15
	Capital work-in-progress	-
	Investment Property	-
	Goodwill	-
	Other Intangible Assets	-
	Intangible assets under development	1.08
	Biological Assets other than bearer plants	-
	Financial Assets	-
	(i) Investments	0.93
	(ii) Trade receivables	231.39
	(iii) Loans and Advances	0.20
	(iv) Deposits	638.95
	(v) Other financial assets	-
	Deferred tax assets (net)	38.89
	Other Non Current Assets	259.49
	<b>Sub Total - Non- Current Assets</b>	<b>3,455.08</b>
<b>II</b>	<b>Current Assets</b>	
	Inventories	8,225.69
	Financial assets	-
	(i) Investments	-
	(ii) Trade receivables	7,498.61
	(iii) Cash and cash equivalents	49.27
	(iv) Bank balances other than Cash and cash equivalents	306.24
	(v) Loan	218.39
	(vi) Other financial assets	1,963.02
	Current tax assets (net)	-
	Other Current assets	1,115.00
	<b>Sub Total - Current Assets</b>	<b>19,376.22</b>
	<b>TOTAL ASSETS</b>	<b>22,831.30</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>	
<b>I</b>	<b>Equity</b>	
	(a) Equity Share Capital	773.50
	(b) Other Equity	4,584.11
	<b>Sub Total - Equity</b>	<b>5,357.61</b>
<b>II</b>	<b>LIABILITIES</b>	
	<b>Non Current Liabilities</b>	
	Financial Liabilities	
	(i) Borrowings	1,199.63
	(ii) Trade payables	-
	(iii) Other Financial liabilities	-
	Provisions	406.36
	Deferred Tax Liabilities (Net)	-
	Other Non current liabilities	420.83
	<b>Sub Total - Non- Current Liabilities</b>	<b>2,026.82</b>
	<b>Current Liabilities</b>	
	Financial Liabilities	
	(i) Borrowings	6,245.94
	(ii) Other Financial liabilities	-
	(iii) Trade payables	6,121.53
	Other Current liabilities	1,862.99
	Provisions	-
	Current tax liabilities(net)	1,216.41
	<b>Sub Total - Current Liabilities</b>	<b>15,446.87</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>22,831.30</b>

#### NOTES

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 14th day of December, 2017 and Statutory Auditors have carried out Limited Review of the same.

2. The un-audited financial results for the quarter ended 30th September, 2017 are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), Interim Financial Reporting notified under provisions of Section 133 of the Companies Act, 2013 read with Rules made thereunder (including amendments thereof) to the extent notified and guidelines issued by Securities and Exchange Board of India (SEBI). The Company has adopted Ind AS w.e.f 1st April, 2017.



3. Figures for the quarter ended 30th September, 2016 have been restated as required in terms of Ind AS and have not been subjected to limited review or audit, as the same is not mandatory as per SEBI's circular dated 5th July, 2016. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended 31st March, 2017

4. Reconciliation of profit after tax for the quarter ended and half year ended 30th September, 2017 between Ind As compliant result as reported above with result reported in previous year is given below: (Rs. In Lakhs)

Particulars	Quarter ended 30/09/2016	Halfended 30/09/2016
A) Net profit as after tax for the period as per previous GAAP	263.71	518.96
B) Effect of transition to Ind AS on statement of Profit and Loss Account		
i) Acturial (gain)/loss on employee defined benefit plans recongnised in "Other Comprehensive Income" (Net Of Tax)	0.17	0.34
ii) Incremental finance cost under EIR method	-0.499	(1.15)
iii) Reversal of ECL provision	2.96	5.93
iv) Others	0.01	(0.30)
iv) Deffred Tax	-0.97	(2.03)
Net profit as after tax for the period as per Ind AS	265.38	521.75
<b>Other Comprehensive income net of tax</b>		
Acturial gain on employee defined plans	(0.17)	(0.34)
Total other comprehensive income net of income tax	(0.17)	(0.34)
<b>Total Comprehensive income for the period</b>	<b>265.21</b>	<b>521.41</b>

5. There is a possibility that these quarterly financial results may require adjustment before constituting the final Ind AS financial statement as at, and for the financial year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standard or interpretations issued by MCA/ appropriate authority or changes in use of one or more optional exemptions from full retrospective application of certain Ind AS as permitted under Ind AS - 101.

6. The previous period/year figures have been regrouped/rearranged wherever necessary to make them comparable.

7. The Board of Directors of the Company at its Board Meeting held on November 09, 2017 approved a Scheme of Amalgamation involving amalgamation of Gufic Lifesciences Private Limited with the Company. The scheme will be effective from the appointed date April 01, 2017, subject to the necessary regulatory approvals and no effect to the same has been given in the books of accounts as yet.

For Gufic Biosciences Limited



Hemal Desai  
CFO & Director  
DIN: 07014744

Place: Mumbai  
Date: 14th December, 2017





**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2017**

Particulars	Quarter Ended 30.09.17 Unaudited	Quarter Ended 30.06.17 Unaudited	Quarter Ended 30.09.16 Unaudited	Quarter Ended 31.12.16 Unaudited	For the Period Ended 30.09.17 Unaudited	For the Period Ended 30.09.16 Unaudited
<b>SEGMENT REVENUE</b>						
Sales & Service						
Pharma	7061.90	5291.92	6134.29	6336.23	12357.87	11644.44
Consumer	0.00	0.00	294.96	161.01	0.00	321.06
Bulk Drug	423.05	1046.44			1469.48	
<b>Total</b>	<b>7484.95</b>	<b>6338.36</b>	<b>6429.25</b>	<b>6497.24</b>	<b>13827.35</b>	<b>11965.50</b>
Unallocable Income	84.83	11.84	15.50	14.67	92.63	30.57
<b>Total Segment Revenue</b>	<b>7569.78</b>	<b>6350.20</b>	<b>6444.75</b>	<b>6511.91</b>	<b>13919.98</b>	<b>11996.07</b>
<b>SEGMENT RESULTS</b>						
Pharma	1341.76	899.63	1488.71	1627.07	2348.00	2740.86
Consumer	0.00		30.39	14.91	0.00	32.77
Bulk Drug	76.15	198.82			264.51	
Unallocabel Income	51.38	107.49			158.87	
<b>TOTAL</b>	<b>1469.29</b>	<b>1205.94</b>	<b>1519.10</b>	<b>1641.98</b>	<b>2771.37</b>	<b>2773.63</b>
Less: Unallocated over heads	357.01	33.61	837.09	963.44	486.75	1448.55
Finance Charges	269.21	175.53	141.41	149.25	444.74	278.32
Excise Charges	0.00	315.52			315.52	
Depreciation	97.67	93.29	93.68	92.54	190.96	184.80
Tax provision	178.71	233.87	183.21	126.62	412.58	343.00
<b>Net Profit after Tax</b>	<b>566.69</b>	<b>354.12</b>	<b>263.21</b>	<b>310.14</b>	<b>920.81</b>	<b>518.96</b>

